Point72 Asset Management
INZY

Point72 Asset Management’s Inozyme Pharma INZY Stock Holding History

Point72 Asset Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-700,000
Closed -$2.94M – 2450
2023
Q3 		$2.94M Buy
+700,000
New +$3.56M 0.01% 1037
2023
Q2 		– Sell
-138
Closed -$791 – 2461
2023
Q1 		$791 Buy
+138
New +$365 ﹤0.01% 2130

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management's INZY Position: Q4 2023 in Review

Point72 Asset Management sold out of Inozyme Pharma (INZY) in Q4 2023, closing a stake of 700,000 shares — an estimated $2.94M sold.

Point72 Asset Management first reported a position in INZY in Q1 2023 and held it in 2 quarters. The position peaked at $2.94M in Q3 2023. 80 funds tracked by Wall St. Rank hold INZY as of Q4 2023.

  • Point72 Asset Management reported no remaining Inozyme Pharma position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 700,000 Inozyme Pharma shares in Q4 2023, an estimated $2.94M.
  • Point72 Asset Management first reported a position in Inozyme Pharma in Q1 2023 and held it in 2 quarters.
  • Point72 Asset Management's Inozyme Pharma position peaked at $2.94M in Q3 2023.
  • 80 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.